 |
77 Diseases |  |
69 Trials |
|
69 Trials |  |
4434 News |  |
| «12...34353637383940414243444546» |
- || Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Phase classification: Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (clinicaltrials.gov) - Jun 21, 2016
P3b, N=500, Recruiting, Sponsor: Gilead Sciences
Phase classification: P3 --> P3b
- rifampicin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment open, Trial primary completion date, Combination therapy: Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin (clinicaltrials.gov) - Jun 13, 2016
P4, N=12, Recruiting, Sponsor: University of Miami
Phase classification: P3 --> P3b Trial primary completion date: Feb 2017 --> Dec 2017 | Not yet recruiting --> Recruiting
- || Tivicay (dolutegravir) / ViiV Healthcare
Phase classification: Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment (clinicaltrials.gov) - Jun 10, 2016
P3b, N=612, Recruiting, Sponsor: ViiV Healthcare
Trial primary completion date: Feb 2017 --> Dec 2017 | Not yet recruiting --> Recruiting Phase classification: P3 --> P3b
- Enrollment closed: Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=52, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Phase classification: P3 --> P3b Recruiting --> Active, not recruiting
- Mycobutin (rifabutin) / Pfizer, Lupin, Isentress (raltegravir) / Merck (MSD)
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV (clinicaltrials.gov) - Jun 10, 2016
P2b, N=71, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Phase classification: P2 --> P2b | N=471 --> 71 | Trial primary completion date: Sep 2016 --> Feb 2016
- || lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed: SIMPLE: The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation (clinicaltrials.gov) - Jun 9, 2016
P=N/A, N=216, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting | Phase classification: P2 --> P2b | N=471 --> 71 | Trial primary completion date: Sep 2016 --> Feb 2016 Recruiting --> Active, not recruiting
- ||||| Vitekta (elvitegravir) / Japan Tobacco, Gilead
Enrollment closed: Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants (clinicaltrials.gov) - May 13, 2016
P2/3, N=90, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | New P4 trial: REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - Apr 13, 2016
P4, N=4000, Recruiting, Sponsor: UMC Utrecht
- nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial primary completion date: Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Populations Using Formula Feeding (PROMISE) (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=1000, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2017 --> Sep 2016
- nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial primary completion date: PROMISE: Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=3485, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Apr 2017 --> Sep 2016 Trial primary completion date: Apr 2017 --> Sep 2016
- nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment open: DATiC: Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) (clinicaltrials.gov) - Mar 30, 2016
P4, N=240, Recruiting, Sponsor: University of Cape Town
Trial primary completion date: Apr 2017 --> Sep 2016 Active, not recruiting --> Recruiting
- Isentress (raltegravir) / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection (clinicaltrials.gov) - Mar 22, 2016
P2, N=9, Completed, Sponsor: McGill University Health Center
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | N=40 --> 9 | Trial primary completion date: Dec 2015 --> Mar 2016
- | New P4 trial: Antiretroviral Regime for Viral Eradication in Newborns (clinicaltrials.gov) - Mar 18, 2016
P4, N=600, Not yet recruiting, Sponsor: National Center for Women and Children's Health, China CDC
- Enrollment change: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Feb 29, 2016
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | N=40 --> 9 | Trial primary completion date: Dec 2015 --> Mar 2016 N=1300 --> 1786
- |||| lopinavir/ritonavir / Generic mfg.
Trial completion, Combination therapy: Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens (clinicaltrials.gov) - Feb 27, 2016
P2, N=300, Completed, Sponsor: Pfizer
N=1300 --> 1786 No longer recruiting --> Completed
- rifampicin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy (clinicaltrials.gov) - Feb 22, 2016
P2, N=40, Completed, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
No longer recruiting --> Completed Active, not recruiting --> Completed
- Mycobutin (rifabutin) / Pfizer, Lupin
Enrollment open: Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly (clinicaltrials.gov) - Feb 22, 2016
P2, N=40, Recruiting, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| lopinavir/ritonavir / Generic mfg.
Trial completion: Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet (clinicaltrials.gov) - Feb 5, 2016
P=N/A, N=3187, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| lopinavir/ritonavir / Generic mfg.
Trial completion, Combination therapy: PROTEKT: Kaletra in Combination With Antiretroviral Agents (clinicaltrials.gov) - Feb 5, 2016
P=N/A, N=531, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected (clinicaltrials.gov) - Feb 2, 2016
P1/2, N=52, Recruiting, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> May 2016
- || darunavir/ritonavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P3 trial: WRHI052: Evaluation of Low-dose Darunavir in a Switch Study (clinicaltrials.gov) - Feb 2, 2016
P3, N=300, Not yet recruiting, Sponsor: Willem Daniel Francois Venter
- | nevirapine / Generic mfg.
Trial completion, Combination therapy: OCTANE: NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission (clinicaltrials.gov) - Feb 1, 2016
P3, N=745, Completed, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Dec 2015 --> May 2016 Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Enrollment open: FIT-2: First-Line Treatment for HIV-2 (clinicaltrials.gov) - Jan 30, 2016
P2b, N=210, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- zidovudine / Generic mfg., nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: PHPT-5: Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand (clinicaltrials.gov) - Jan 28, 2016
P3, N=435, Terminated, Sponsor: Institut de Recherche pour le Developpement
Not yet recruiting --> Recruiting N=2097 --> 435
- Enrollment open: LEOPARD: Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=60, Recruiting, Sponsor: Columbia University
N=2097 --> 435 Not yet recruiting --> Recruiting
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion, Trial primary completion date: MARCH Central Nervous System Substudy (clinicaltrials.gov) - Jan 20, 2016
P=N/A, N=28, Completed, Sponsor: Kirby Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015
- || lopinavir/ritonavir / Generic mfg.
Trial primary completion date, Adherence: Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program (clinicaltrials.gov) - Jan 17, 2016
P=N/A, N=165, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015 Trial primary completion date: Dec 2015 --> Sep 2016
- || lopinavir/ritonavir / Generic mfg.
Trial initiation date, Combination therapy: PROTEKT: Kaletra in Combination With Antiretroviral Agents (clinicaltrials.gov) - Jan 11, 2016
P=N/A, N=450, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2015 --> Sep 2016 Initiation date: Jun 2006 --> Sep 2008
- ||| lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment open: SIMPLE: The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation (clinicaltrials.gov) - Jan 11, 2016
P=N/A, N=216, Recruiting, Sponsor: AbbVie
Initiation date: Jun 2006 --> Sep 2008 Not yet recruiting --> Recruiting
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ? 60 Years (clinicaltrials.gov) - Jan 7, 2016
P3, N=150, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- rifampicin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial initiation date, Combination therapy: Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin (clinicaltrials.gov) - Dec 18, 2015
P4, N=12, Not yet recruiting, Sponsor: University of Miami
Not yet recruiting --> Recruiting Initiation date: Jul 2014 --> Jan 2016
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (clinicaltrials.gov) - Dec 16, 2015
P3, N=300, Recruiting, Sponsor: Gilead Sciences
Initiation date: Jul 2014 --> Jan 2016 Not yet recruiting --> Recruiting
- efavirenz / Generic mfg.
New P1 trial: PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers (clinicaltrials.gov) - Dec 16, 2015
P1, N=50, Recruiting, Sponsor: St Stephens Aids Trust
- Isentress (raltegravir) / Merck (MSD)
Trial initiation date, Trial primary completion date: FIT-2: First-Line Treatment for HIV-2 (clinicaltrials.gov) - Dec 10, 2015
P2b, N=210, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Recruiting Initiation date: Sep 2015 --> Jan 2016 | Trial primary completion date: Dec 2018 --> Jan 2018
- efavirenz / Generic mfg.
Trial completion: LAAM-HAART PET Imaging (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=10, Completed, Sponsor: Washington University School of Medicine
Initiation date: Sep 2015 --> Jan 2016 | Trial primary completion date: Dec 2018 --> Jan 2018 Active, not recruiting --> Completed
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Enrollment change: Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=13, Completed, Sponsor: University of Alberta
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=80 --> 13
- | lopinavir/ritonavir / Generic mfg.
Trial completion: Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women (clinicaltrials.gov) - Dec 3, 2015
P=N/A, N=116, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | N=80 --> 13 Active, not recruiting --> Completed
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ? 60 Years (clinicaltrials.gov) - Nov 30, 2015
P3, N=150, Not yet recruiting, Sponsor: Gilead Sciences
- | Viracept (nelfinavir) / ViiV Healthcare, Roche, NN1213 / Novo Nordisk
Trial completion: Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (clinicaltrials.gov) - Nov 24, 2015
P2/3, N=266, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (clinicaltrials.gov) - Nov 17, 2015
P3, N=300, Not yet recruiting, Sponsor: Gilead Sciences
- lopinavir/ritonavir / Generic mfg.
Enrollment status: IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children (clinicaltrials.gov) - Oct 28, 2015
P4, N=50, Enrolling by invitation, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Active, not recruiting --> Completed Recruiting --> Enrolling by invitation
- ||| lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
New trial: SIMPLE: The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=216, Not yet recruiting, Sponsor: AbbVie
- ||| Isentress (raltegravir) / Merck (MSD)
Enrollment closed: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Oct 8, 2015
P2, N=100, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- lopinavir/ritonavir / Generic mfg.
Enrollment open, Trial primary completion date: IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children (clinicaltrials.gov) - Oct 7, 2015
P4, N=50, Recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2016 --> Dec 2016
- || lopinavir/ritonavir / Generic mfg.
Enrollment closed, Adherence: Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program (clinicaltrials.gov) - Oct 6, 2015
P=N/A, N=165, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- |||| lopinavir/ritonavir / Generic mfg.
Trial completion, Trial primary completion date: Induction-maintenance of Lopinavir/r in HIV-infected Subjects (clinicaltrials.gov) - Sep 8, 2015
P4, N=100, Completed, Sponsor: The Huesped Foundation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2008 --> Dec 2009
- nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed, Trial primary completion date: DATiC: Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) (clinicaltrials.gov) - Sep 1, 2015
P4, N=240, Active, not recruiting, Sponsor: University of Cape Town
Active, not recruiting --> Completed | Trial primary completion date: Dec 2008 --> Dec 2009 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Jul 2017
- |||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (clinicaltrials.gov) - Aug 21, 2015
P3, N=665, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Jul 2017 Trial primary completion date: Nov 2015 --> Aug 2015
- Isentress (raltegravir) / Merck (MSD)
Trial initiation date, Trial primary completion date: FIT-2: First-Line Treatment for HIV-2 (clinicaltrials.gov) - Aug 13, 2015
P2b, N=210, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Nov 2015 --> Aug 2015 Initiation date: Sep 2014 --> Sep 2015 | Trial primary completion date: Dec 2017 --> Dec 2018
- | NN1213 / Novo Nordisk
Trial completion, Discordant: Preventing Sexual Transmission of HIV With Anti-HIV Drugs (clinicaltrials.gov) - Aug 13, 2015
P3, N=3500, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Sep 2014 --> Sep 2015 | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed